Hangzhou Tigermed Consulting Future Growth
Future criteria checks 2/6
Hangzhou Tigermed Consulting is forecast to grow earnings and revenue by 19.5% and 15% per annum respectively. EPS is expected to grow by 19% per annum. Return on equity is forecast to be 10.2% in 3 years.
Key information
19.5%
Earnings growth rate
19.0%
EPS growth rate
| Life Sciences earnings growth | 30.2% |
| Revenue growth rate | 15.0% |
| Future return on equity | 10.2% |
| Analyst coverage | Good |
| Last updated | 02 May 2024 |
Recent future growth updates
Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 28
Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Apr 01Recent updates
Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 28Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Apr 08Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues
Apr 04Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Apr 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11,408 | 2,868 | 2,215 | 2,575 | 14 |
| 12/31/2025 | 9,919 | 2,583 | 2,276 | 2,368 | 21 |
| 12/31/2024 | 8,197 | 2,034 | 1,862 | 2,139 | 10 |
| 3/31/2024 | 7,240 | 1,691 | 924 | 1,266 | N/A |
| 12/31/2023 | 7,384 | 2,025 | 837 | 1,150 | N/A |
| 9/30/2023 | 7,330 | 2,281 | 866 | 1,205 | N/A |
| 6/30/2023 | 7,202 | 2,203 | 964 | 1,373 | N/A |
| 3/31/2023 | 7,072 | 2,057 | 613 | 1,083 | N/A |
| 1/1/2023 | 7,085 | 2,007 | 909 | 1,358 | N/A |
| 9/30/2022 | 7,225 | 2,698 | 1,098 | 1,521 | N/A |
| 6/30/2022 | 6,751 | 2,811 | 917 | 1,299 | N/A |
| 3/31/2022 | 6,129 | 2,937 | 1,189 | 1,489 | N/A |
| 1/1/2022 | 5,214 | 2,874 | 1,055 | 1,424 | N/A |
| 9/30/2021 | 4,287 | 2,213 | 930 | 1,210 | N/A |
| 6/30/2021 | 3,797 | 2,006 | 976 | 1,263 | N/A |
| 3/31/2021 | 3,444 | 1,950 | 895 | 1,148 | N/A |
| 12/31/2020 | 3,192 | 1,750 | 842 | 999 | N/A |
| 9/30/2020 | 3,073 | 1,632 | 558 | 704 | N/A |
| 6/30/2020 | 2,918 | 1,488 | 524 | 621 | N/A |
| 3/31/2020 | 2,845 | 951 | 452 | 565 | N/A |
| 12/31/2019 | 2,803 | 842 | 425 | 528 | N/A |
| 9/30/2019 | 2,737 | 682 | 386 | 518 | N/A |
| 6/30/2019 | 2,605 | 606 | 356 | 450 | N/A |
| 3/31/2019 | 2,436 | 522 | 387 | 488 | N/A |
| 12/31/2018 | 2,301 | 472 | 431 | 522 | N/A |
| 9/30/2018 | 2,107 | 419 | 458 | 521 | N/A |
| 6/30/2018 | 1,977 | 400 | 333 | 404 | N/A |
| 3/31/2018 | 1,805 | 354 | 255 | 312 | N/A |
| 12/31/2017 | 1,687 | 301 | N/A | 315 | N/A |
| 9/30/2017 | 1,500 | 241 | N/A | 272 | N/A |
| 6/30/2017 | 1,352 | 182 | N/A | 281 | N/A |
| 3/31/2017 | 1,255 | 144 | N/A | 305 | N/A |
| 12/31/2016 | 1,175 | 141 | N/A | 192 | N/A |
| 9/30/2016 | 1,150 | 145 | N/A | 176 | N/A |
| 6/30/2016 | 1,096 | 159 | N/A | 156 | N/A |
| 3/31/2016 | 1,015 | 161 | N/A | 135 | N/A |
| 12/31/2015 | 957 | 156 | N/A | 186 | N/A |
| 9/30/2015 | 862 | 151 | N/A | 98 | N/A |
| 6/30/2015 | 821 | 147 | N/A | 100 | N/A |
| 3/31/2015 | 725 | 135 | N/A | 87 | N/A |
| 12/31/2014 | 625 | 125 | N/A | 44 | N/A |
| 9/30/2014 | 510 | 112 | N/A | 46 | N/A |
| 6/30/2014 | 401 | 102 | N/A | 59 | N/A |
| 3/31/2014 | 377 | 99 | N/A | 57 | N/A |
| 12/31/2013 | 337 | 94 | N/A | 77 | N/A |
| 9/30/2013 | 314 | 89 | N/A | 40 | N/A |
| 6/30/2013 | 299 | 82 | N/A | 20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300347's forecast earnings growth (19.5% per year) is above the savings rate (2.9%).
Earnings vs Market: 300347's earnings (19.5% per year) are forecast to grow slower than the CN market (24.1% per year).
High Growth Earnings: 300347's earnings are forecast to grow, but not significantly.
Revenue vs Market: 300347's revenue (15% per year) is forecast to grow faster than the CN market (14.7% per year).
High Growth Revenue: 300347's revenue (15% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300347's Return on Equity is forecast to be low in 3 years time (10.2%).